宫颈癌术后输注细胞因子诱导的杀伤细胞治疗前后外周血免疫指标的变化

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (976 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要目的观察鳞癌、腺癌、腺鳞癌3种类型宫颈癌根治术后使用细胞因子诱导的杀伤细胞(cytokine induced killer,CIK)治疗前后外周血中免疫指标的变化,为临床使用CIK治疗宫颈癌效果评估提供依据。方法收集我院2014-01至2016-05肿瘤科和妇产科行宫颈癌根治术后患者98例(其中鳞癌56例,腺癌25例,腺鳞癌17例)CIK治疗前1 d和治疗1个周期后的外周血各5 ml,收集的外周血按CIK细胞治疗流程进行血清分离,分离后的血清用流式细胞计数仪对血清中CD3⁺、CD4⁺、CD8⁺、CD4/CD8、NK细胞的比例进行检测分析。结果 (1)98例宫颈癌根治术后使用CIK细胞治疗前后外周血中免疫指标的对比显示CD3⁺、NK细胞的比例均升高,CD4⁺、CD4/CD8比例仅在鳞癌和腺癌中升高,CD8⁺治疗前后变化不明显。(2)以CD3⁺和NK细胞为例可以看出使用CIK细胞治疗后腺癌免疫指标较鳞癌、腺鳞癌有显著提升(P<0.05),鳞癌治疗前后,CD3⁺:(60.71±5.84)/(67.27±3.04),NK细胞:(8.92±3.64)/(12.93±6.25);腺癌治疗前后,CD3⁺:(59.91±2.49)/(68.32±8.24),NK细胞:(9.04±5.31)/(17.87±6.46);腺鳞癌治疗前后,CD3⁺:(59.01±5.90)/(65.23±7.07),NK细胞:(8.59±3.97)/(15.07±2.71)。结论 CIK 细胞治疗可以显著提升宫颈癌根治术后患者的免疫功能,对延长生存期,提高生存质量具有重要意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵花
	刘征丽
	许霞

关键词 ：细胞因子诱导的杀伤细胞, 宫颈癌, 免疫指标

Abstract：Objective To observe the changes of immune parameters of patients with different cervical cancer treated with cytokine-induced killer(CIK)cells after radical hysterectomy in order to provide data for clinical evaluation.Methods 50 ml peripheral blood was collected the day before CIK cell therapy and after a course of treatment from ninety-eight radical hysterectomy patients(56 cases of squamous carcinoma, 25 cases of adenocarcinoma,and 17 cases of adenosquamous carcinoma) treated in the Department of Gynaecology and Obstetrics and Department of Oncology between January 2014 and September 2016.According to the process of CIK cell therapy, the serum was separated, and the proportion of CD3⁺、CD4⁺、CD8⁺、CD4/CD8、and NK cells in the serum was analyzed using flow cytometry (FCM).Results 1.The proportion of CD3⁺ and NK cells in the 98 patients was increased after CIK cell therapy.The proportion of CD4⁺ and CD4/CD8 rose only in patients of squamous carcinoma and adenocarcinoma.The proportion of CD8⁺ did not change significantly.2.The result of CD3⁺ and NK cells suggested that after treatment the immune parameters in patients of adenocarcinoma were significantly higher than those in patients of squamous carcinoma and adenosquamous carcinoma (P<0.05).After treatment, CD3⁺ and NK cells increased from 60.71±5.84 to 67.27±3.04 and from 8.92±3.64 to 12.93±6.25 respectively in patients of squamous carcinoma, from 59.91±2.49 to 68.32±8.24 and from 9.04±5.31 to 17.87±6.46 respectively in patients of adenocarcinoma,and finally from 59.01±5.90 to 65.23±7.07 and from 59±3.97 to 15.07±2.71 respectively in patients of adenosquamous carcinoma.Conclusions CIK cell therapy can markedly enhance the immunity of patients after radical hysterectomy. It’s of great significance for improving the quality of survival.

Key words： cytokine induced killer cervical cancer immune parameters

收稿日期: 2016-08-11

ZTFLH:

R737.3

作者简介: 赵花,本科学历,主管技师。

引用本文:

赵花,刘征丽,许霞. 宫颈癌术后输注细胞因子诱导的杀伤细胞治疗前后外周血免疫指标的变化[J]. 武警医学, 2017, 28(4): 358-360. ZHAO Hua,LIU Zhengli,and XU Xia. Changes of immune parameters in cervical cancer patients after CIK cell therapy. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(4): 358-360.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2017/V28/I4/358

[1]	雷张涛,叶红.宫颈癌肿瘤干细胞的研究进展[J]. 医学综述, 2012, 7(8): 1156-1158.
[2]	Antill Y C,Dowty J G,Win A K, et al. Lynch Syndrome and Cervical Cancer[J]. Int J Cancer, 2015, 137(11): 2757-2761.
[3]	Schmeel L C,Schmeel F C,Coch C, et al. Cytokine-induced Killer (cik) Cells in Cancer Immunotherapy: Report of the International Registry on Cik Cells (ircc)[J]. J Cancer Res and Clin Oncol, 2015, 141(5): 839-849.
[4]	Dasari S,Wudayagiri R,Valluru L. Cervical Cancer: Biomarkers for Diagnosis and Treatment[J]. Clin Chim Acta, 2015, 445(9): 7-11.
[5]	罗光华,马鸣,郭莉莉,等. CIK细胞治疗对肿瘤患者外周血免疫细胞亚型的影响[J]. 中国肿瘤生物治疗杂志, 2013, 12(4): 475-477.
[6]	吕晓霞,陈帼玲,王学群,等. 自体CIK细胞治疗21例中晚期恶性实体瘤的肿瘤标志物变化观察[J]. 中华细胞与干细胞杂志, 2014, 7(3): 165-174.
[7]	林兰,刘继斌. 中晚期消化系恶性肿瘤CIK细胞治疗前后免疫功能变化的价值[J]. 肿瘤基础与临床, 2010, 12(5): 399-401.
[8]	赵华,贾咏梅. DC-CIK免疫治疗联合常规化疗对非小细胞肺癌患者血清学及外周血免疫功能指标的影响[J]. 海南医学院学报, 2015, 6(7): 967-970.
[9]	苏小岩,胡艳,张文涛,等. DC-CIK细胞免疫治疗联合放疗治疗中晚期宫颈癌的疗效观察[J]. 长江大学学报(自科版), 2014, 4(33): 4, 77-79.
[10]	田志刚. 基于NK细胞的肿瘤免疫治疗研究进展[J]. 中国肿瘤生物治疗杂志,2009,1:2-5.
[11]	周怡,蒋敬庭. 细胞因子在CIK细胞抗肿瘤治疗中的作用[J]. 临床检验杂志,2014,32(2):115-117.
[12]	邢宏,韩方正,汪莉萍. 细胞因子诱导的杀伤细胞CIK的基础与临床研究新进展[J].中国免疫学杂志,2011,27(1):88-92.
[13]	张丽鹏,李新伟,黄宽军,等. DC-CIK细胞免疫治疗晚期结直肠癌患者的远期疗效及影响因素分析[J].现代生物医学进展,2016,22(16):4348-4351.
[14]	李晓英,鲍杨漪,江蓓蕾,等. 不同类型肿瘤患者自体CIK 细胞治疗对机体免疫状态及临床症状改善的影响[J].安徽医科大学学报,2012,47(4):434-437.
[15]	Akyol M,Ulger E,Alacacioglu A,et al.Quality of life in colorectal cancer patients:an Izmir Oncology Group (IZOG)study[J]. J Buon,2015,20(4):1015-1022.